Thomas Eastling

Thomas Wilson Eastling is currently Director at Shanghai Genomics, Inc. since 2015; Chief Financial Officer, Secretary & Director at Berkeley Advanced Biomaterials, Inc. since 2017; Director at GNI Group Ltd. since 2022; Non-Executive Director at Continent Pharmaceutical, Inc. since 2015; Director at GNI Hong Kong Ltd. since 2015; Chief Financial Officer & Director at Cullgen, Inc. since 2018; Director at Shanghai GEP Pharmaceuticals, Inc. since 2018; Member of the National Association of Corporate Directors; Chief Financial Officer & Secretary at GNI USA, Inc. since 2015; Chief Financial Officer & Head-Investor Relations at Cullgen, Inc. (New); and Chief Financial Officer at Gyre Therapeutics, Inc. starting in 2023.
Former positions include Managing Director & Senior Vice President-Japan at Duff & Phelps Credit Rating Co. from 1999 to 2000; Managing Director at Fitch Group, Inc.; Director at Catalyst Biosciences, Inc.; Independent Director at Kai Wo Asset Management Ltd.; and MD-Strategic Planning & Investor Relations at SoftBank Corp.
from 2001 to 2003.
Education includes a graduate degree from Thunderbird School of Global Management conferred in 1983 and an undergraduate degree from the University of Southern California conferred in 1981.